current page

Newsroom 2019

February 19, 2019

Terumo Cardiovascular Group and Hemostasis Introduce BoneSeal® Bone Hemostat
Advanced synthetic bioabsorbable solution controls bleeding during sternotomy procedures and promotes bone growth during post-operative healing1

ANN ARBOR, MICH. — February 19, 2019 — Terumo Cardiovascular Group, a global leader in cardiovascular surgery technologies, and Hemostasis, LLC., today announced a three-year exclusive distribution agreement that will bring BoneSeal® bone hemostat to the United States cardiac surgery market. BoneSeal hemostat is used as a mechanical barrier to control bleeding from cut or damaged bone surfaces. It is comprised of a blend of resorbable, synthetic polymers and biocompatible minerals that promotes bone growth.1


BoneSeal hemostat is a new generation of bone hemostat that effectively stops bleeding upon application during sternotomy procedures and promotes bone growth during post-operative healing.1

Cardiac surgeons have long-attempted to use various hemostats to manage bleeding from sternotomies, including beeswax, putties, powders and gelatin. BoneSeal hemostat offers a new, all-in-one solution to manage bone hemostasis that is easy to apply and bioabsorbable.

"Terumo CV Group is excited to partner with Hemostasis to bring this innovative product to cardiac surgeons," said Robert DeRyke, Terumo Cardiovascular Group’s President and CEO. "Our new agreement to distribute BoneSeal hemostat is yet another way we can positively impact patient care."

BoneSeal hemostat handles much like beeswax and works immediately to achieve bone hemostasis upon application. With BoneSeal hemostat, surgeons can take control of hemostasis and post-operative bleeding, giving patients a better start to healing.1

  1. Tham T, Roberts K, Shanahan J, Burban J, Constantino P. Analysis of bone healing with a novel bone wax substitute compared with bone wax in a porcine bone defect model. Future Science OA. 2018 Sep; 4(8): FSO326.

About Terumo Cardiovascular Group

Terumo Cardiovascular Group manufactures and markets medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass, intra-operative monitoring and vascular grafting. The company is headquartered in Ann Arbor, Michigan, with manufacturing operations in the U.S., Europe and Asia. It is one of several subsidiaries of Terumo Corporation of Japan that is focused exclusively on cardiac and vascular specialties. For more information, visit .

About Hemostasis

Hemostasis designs and manufactures advanced biomaterial-based technologies to facilitate hemostasis and wound healing. Hemostasis products are used in procedures to treat disorders and stop bleeding in sinus, cardiac, orthopedic, vascular, soft tissue and solid organs. Hemostasis is headquartered in Saint Paul, Minnesota. For more information, visit

(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.


Return to page top